Scarica l'app Stockscreener
1.73
15.33%
0.23
Dopo l'orario di chiusura:
1.72
-0.01
-0.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.50
Aprire:
$1.5
Volume 24 ore:
2.83M
Relative Volume:
2.91
Capitalizzazione di mercato:
$95.39M
Reddito:
-
Utile/perdita netta:
$-30.04M
Rapporto P/E:
-1.0949
EPS:
-1.58
Flusso di cassa netto:
$-27.38M
1 W Prestazione:
+26.28%
1M Prestazione:
+35.16%
6M Prestazione:
+7.45%
1 anno Prestazione:
-39.93%
Intervallo 1D:
$1.48
$1.75
Intervallo di 1 settimana:
$1.27
$2.05
Portata 52W:
$0.8301
$2.91
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Nome
Regulus Therapeutics Inc
Settore
Industria
Telefono
858-202-6300
Indirizzo
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Confronta RGLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
1.73 | 95.39M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-02 | Iniziato | Oppenheimer | Outperform |
| 2024-03-18 | Iniziato | Leerink Partners | Outperform |
| 2018-03-28 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | Iniziato | Leerink Partners | Outperform |
| 2017-06-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-06 | Reiterato | Wedbush | Outperform |
| 2017-01-30 | Downgrade | Needham | Buy → Hold |
| 2017-01-30 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | Reiterato | Chardan Capital Markets | Buy |
| 2016-11-02 | Reiterato | Needham | Buy |
| 2016-07-25 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | FBR Capital | Outperform |
| 2016-06-28 | Reiterato | Needham | Buy |
| 2016-06-07 | Reiterato | Chardan Capital Markets | Buy |
| 2016-04-13 | Iniziato | Chardan Capital Markets | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-06-09 | Iniziato | Guggenheim | Buy |
| 2015-04-21 | Ripresa | FBR Capital | Outperform |
| 2014-11-24 | Iniziato | Deutsche Bank | Buy |
| 2014-08-07 | Reiterato | FBR Capital | Outperform |
| 2013-08-14 | Reiterato | Needham | Buy |
Mostra tutto
Regulus Therapeutics Inc Borsa (RGLS) Ultime notizie
Wells Fargo Upgrades Regulus Therapeutics (RGLS) - Nasdaq
Regulus Therapeutics (RGLS) Announces Promising Phase 1b Trial R - GuruFocus.com
Regulus stock jumps after Phase 1 data update (RGLS:NASDAQ) - Seeking Alpha
Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise - Marketscreener.com
Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease - Marketscreener.com
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease - Benzinga
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD - StreetInsider.com
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose Clinical Trial of Farabursen for the Treatment of Autosomal Dominant Polycystic Kidney Disease - Marketscreener.com
Regulus Announces Positive Phase 1b Study Results - TipRanks
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Dis - StreetInsider.com
Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial - StockTitan
Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey
Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from Canaccord Genuity Group - Defense World
HC Wainwright Reaffirms “Buy” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth? - Yahoo Finance
Regulus Therapeutics Reports Positive Trial Results and Financials - TipRanks
Regulus: Q4 Earnings Snapshot - The Bakersfield Californian
Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
Regulus Therapeutics Inc. SEC 10-K Report - TradingView
Regulus: Q4 Earnings Snapshot -March 13, 2025 at 04:19 pm EDT - Marketscreener.com
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PR Newswire
Regulus Therapeutics (RGLS) to Release Quarterly Earnings on Thursday - Defense World
Rhumbline Advisers Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeutics, Reata Pharma - Barchart
AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical - openPR
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference - PR Newswire
Can Regulus Therapeutics' Conference Appearance Signal New MicroRNA Developments? - StockTitan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Regulus Therapeutics’ (RGLS) Buy Rating Reiterated at HC Wainwright - Defense World
RNAi Therapeutics and Technology Market Top Companies Study - openPR
Promising Phase 1b Results and FDA Alignment Drive Buy Rating for Regulus Therapeutics - TipRanks
Polycystic Kidney Disease Pipeline 2025: FDA Approvals - openPR
Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
10 Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
Pre-market Movers In Healthcare Sector: ACER, AZRX, RUBY, ADTX, RGLS… - RTTNews
Checking in on Regulus Therapeutics Inc (RGLS) after recent insiders movement - Knox Daily
Is Regulus Therapeutics Inc (NASDAQ: RGLS) Stock Worth Investing In for High Returns? - Marketing Sentinel
RGLS’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Regulus Therapeutics Inc (RGLS) Stock: A Year of Highs and Lows - The InvestChronicle
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Morningstar
Regulus Management Takes Center Stage at Major Healthcare ConferenceKey Details Inside - StockTitan
Regulus Therapeutics Inc. (NASDAQ:RGLS) Director David Baltimore Acquires 19,610 Shares - MarketBeat
Insider Buying: Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Acquires 50,000 Shares of Stock - MarketBeat
JPMorgan Chase & Co. Raises Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Insider Moves Spark Interest: Is Regulus Therapeutics Set for a Comeback? - Jomfruland.net
Insiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00 - Yahoo Finance
CEO & Director of Regulus Therapeutics Joseph Hagan Buys 24% More Shares - Simply Wall St
Insider Buying: David Baltimore Acquires Shares of Regulus Thera - GuruFocus.com
Regulus Therapeutics Inc Azioni (RGLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):